股本结构
单位：万股
| 公告日期 | 2024-04-25 | 2024-02-28 | 2024-01-08 | 2024-01-08 | 2024-02-28 | 2024-01-04 |
|---|---|---|---|---|---|---|
| 证券总股本 | 5438.83 | 5430.06 | 5392.44 | 4614.66 | 4403.83 | 4400.16 |
| 普通股本 | 5438.83 | 5430.06 | 5392.44 | 4614.66 | 4403.83 | 4400.16 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-08 | 2024-02-21 | 2024-01-09 | 2024-01-03 | 2023-12-31 | 2023-11-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-25 | 5438.83 | 未披露 | 定期报告 | 2024-04-08 |
| 2024-02-28 | 5430.06 | 未披露 | 定期报告 | 2024-02-21 |
| 2024-01-08 | 5392.44 | 未披露 |
更多>>
Common stock offered 7,777,778 shares by the company
|
2024-01-09 |
| 2024-01-08 | 4614.66 | 未披露 | 定期报告 | 2024-01-03 |
| 2024-02-28 | 4403.83 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Exercises of vested stock options
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement
Issuance of common stock under ESPP
Vesting of restricted stock units
|
2023-12-31 |
| 2024-01-04 | 4400.16 | 未披露 | 定期报告 | 2023-11-30 |
| 2023-11-06 | 4399.54 | 未披露 | 定期报告 | 2023-10-30 |
| 2023-11-06 | 4390.92 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Exercises of vested stock options
Vesting of restricted stock units
|
2023-09-30 |
| 2023-08-03 | 4390.05 | 未披露 | 定期报告 | 2023-07-28 |
| 2023-08-03 | 4375.94 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock under ESPP
Exercises of vested stock options
Vesting of restricted stock units
|
2023-06-30 |
| 2023-05-09 | 4353.56 | 未披露 | 定期报告 | 2023-05-01 |
| 2023-04-27 | 4351.55 | 未披露 | 定期报告 | 2023-04-10 |
| 2023-05-09 | 4343.59 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement
|
2023-03-31 |
| 2023-03-07 | 4329.34 | 未披露 | 定期报告 | 2023-03-01 |
| 2023-03-07 | 3861.39 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock under ESPP
|
2022-12-31 |
| 2022-11-15 | 3860.73 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-08 | 3852.03 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercises of vested stock options
Vesting of restricted stock units
|
2022-09-30 |
| 2022-08-04 | 3864.76 | 未披露 | 定期报告 | 2022-08-01 |
| 2022-08-04 | 3843.93 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
|
2022-06-30 |
| 2022-05-04 | 3845.61 | 未披露 | 定期报告 | 2022-04-29 |
| 2022-04-21 | 3840.30 | 未披露 | 定期报告 | 2022-04-11 |
| 2022-05-04 | 3824.20 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercises of vested stock options
Vesting of restricted stock units
|
2022-03-31 |
| 2022-03-08 | 3811.47 | 未披露 | 定期报告 | 2022-03-02 |
| 2022-03-08 | 3791.84 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock under ESPP
|
2021-12-31 |
| 2021-11-02 | 3795.74 | 未披露 | 定期报告 | 2021-10-28 |
| 2021-11-02 | 3778.18 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Vesting of restricted stock units
|
2021-09-30 |
| 2021-08-09 | 3793.56 | 未披露 | 定期报告 | 2021-08-04 |
| 2021-08-09 | 3777.22 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock under ESPP
Vesting of restricted stock units
|
2021-06-30 |
| 2021-04-22 | 3772.82 | 未披露 | 定期报告 | 2021-04-09 |
| 2021-05-10 | 3755.61 | 未披露 |
更多>>
from December 31, 2020 to March 31, 2021
Exercises of vested stock options
Vesting of restricted stock units
|
2021-03-31 |
| 2021-02-25 | 3765.38 | 未披露 | 定期报告 | 2021-02-19 |
| 2021-02-25 | 3736.80 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
|
2020-12-31 |
| 2020-11-09 | 3746.58 | 未披露 | 定期报告 | 2020-11-04 |
| 2020-11-09 | 3726.27 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercises of vested stock options
Vesting of restricted stock units
|
2020-09-30 |
| 2020-08-10 | 3743.10 | 未披露 | 定期报告 | 2020-08-05 |
| 2020-08-10 | 3720.36 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
|
2020-06-30 |
| 2020-05-06 | 3719.07 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-04-22 | 3716.46 | 未披露 | 定期报告 | 2020-04-06 |
| 2020-05-06 | 3697.68 | 未披露 |
更多>>
from December 31, 2019 to March 31, 2020
Exercises of vested stock options
Vesting of restricted stock units
|
2020-03-31 |
| 2020-03-03 | 3715.32 | 未披露 | 定期报告 | 2020-02-28 |
| 2020-03-03 | 3686.51 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Exercises of vested stock options
Issuance of common stock in connection with the Neurocrine Collaboration Agreement
Issuance of common stock under ESPP
|
2019-12-31 |
| 2019-11-06 | 3707.33 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-06 | 3682.81 | 未披露 |
更多>>
From June 30, 2019 to September 30, 2019
Exercises of vested stock options
|
2019-09-30 |
| 2019-08-09 | 3693.39 | 未披露 | 定期报告 | 2019-08-02 |
| 2019-08-09 | 3667.76 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Exercises of vested stock options
Issuance of common stock under ESPP
|
2019-06-30 |
| 2019-05-07 | 3683.24 | 未披露 | 定期报告 | 2019-05-03 |
| 2019-04-23 | 3683.06 | 未披露 | 定期报告 | 2019-04-18 |
| 2019-05-07 | 3657.60 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Exercises of vested stock options
Issuance of common stock in connection with the Neurocrine Collaboration Agreement
|
2019-03-31 |
| 2019-02-26 | 3261.70 | 未披露 | 定期报告 | 2019-02-22 |
| 2019-02-26 | 3236.49 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock under ESPP
|
2018-12-31 |
| 2018-11-07 | 3255.69 | 未披露 | 定期报告 | 2018-11-02 |
| 2018-11-07 | 3230.97 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-07 | 3243.60 | 未披露 | 定期报告 | 2018-08-03 |
| 2018-08-07 | 3206.39 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-10 | 3232.10 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-04-27 | 3231.55 | 未披露 | 定期报告 | 2018-04-23 |
| 2018-05-10 | 3188.90 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-03-14 | 3220.68 | 未披露 | 定期报告 | 2018-03-09 |
| 2018-03-14 | 3157.20 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock under ESPP
Issuance of common stock from public offering (net of underwriters discounts and issuance costs of $4,100)
|
2017-12-31 |
| 2017-11-02 | 2694.95 | 未披露 | 定期报告 | 2017-10-30 |
| 2017-11-02 | 2625.03 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-08 | 2690.37 | 未披露 | 定期报告 | 2017-08-04 |
| 2017-08-08 | 2600.29 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 2685.29 | 未披露 | 定期报告 | 2017-05-05 |
| 2017-04-25 | 2685.16 | 未披露 | 定期报告 | 2017-04-19 |
| 2017-05-09 | 2585.18 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-03-15 | 2684.89 | 未披露 | 定期报告 | 2017-03-10 |
| 2017-03-15 | 2559.79 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Vesting of restricted stock
Exercises of vested stock options
|
2016-12-31 |
| 2016-11-10 | 2672.01 | 未披露 | 定期报告 | 2016-11-07 |
| 2016-11-10 | 2541.92 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-11 | 2672.85 | 未披露 | 定期报告 | 2016-08-05 |
| 2016-08-11 | 2527.63 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-04-22 | 2674.97 | 未披露 | 定期报告 | 2016-04-20 |
| 2016-05-12 | 2512.34 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-17 | 2674.92 | 未披露 | 定期报告 | 2016-03-14 |
| 2016-03-17 | 2493.10 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of Series A preferred stock, net of issuance costs of $1
Issuance of Series B preferred stock, net of discount of $5,000 and issuance costs of $220
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock from initial public offering (net of underwriters, discounts, and issuance costs)
Conversion of redeemable convertible preferred stock to common stock
A 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015
|
2015-12-31 |
| 2015-12-17 | 2674.92 | 未披露 | 定期报告 | 2015-12-15 |
| 2015-11-12 | 2603.47 | 未披露 |
更多>>
The conversion of all outstanding convertible preferred stock into 17,647,054 shares of common stock immediately prior to the completion of this offering;
A 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015.
|
2015-11-11 |
| 2015-12-17 | 136.97 | 7500.00 |
更多>>
a 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015
|
2015-10-30 |
| 2015-10-09 | 521.62 | 7500.00 | 定期报告 | 2015-06-30 |
Common stock offered 7,777,778 shares by the company
From December 31, 2022 to December 31, 2023
Exercises of vested stock options
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement
Issuance of common stock under ESPP
Vesting of restricted stock units
From June 30, 2023 to September 30, 2023
Exercises of vested stock options
Vesting of restricted stock units
From March 31, 2023 to June 30, 2023
Issuance of common stock under ESPP
Exercises of vested stock options
Vesting of restricted stock units
From December 31, 2022 to March 31, 2023
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement
From December 31, 2021 to December 31, 2022
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock under ESPP
From June 30, 2022 to September 30, 2022
Exercises of vested stock options
Vesting of restricted stock units
From March 31, 2022 to June 30, 2022
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
From December 31, 2021 to March 31, 2022
Exercises of vested stock options
Vesting of restricted stock units
From December 31, 2020 to December 31, 2021
Vesting of restricted stock units
Exercises of vested stock options
Issuance of common stock under ESPP
From June 30, 2021 to September 30, 2021
Vesting of restricted stock units
From March 31, 2021 to June 30, 2021
Issuance of common stock under ESPP
Vesting of restricted stock units
from December 31, 2020 to March 31, 2021
Exercises of vested stock options
Vesting of restricted stock units
from December 31, 2019 to December 31, 2020
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
From June 30, 2020 to September 30, 2020
Exercises of vested stock options
Vesting of restricted stock units
From March 31, 2020 to June 30, 2020
Exercises of vested stock options
Vesting of restricted stock units
Issuance of common stock under ESPP
from December 31, 2019 to March 31, 2020
Exercises of vested stock options
Vesting of restricted stock units
from December 31, 2018 to December 31, 2019
Exercises of vested stock options
Issuance of common stock in connection with the Neurocrine Collaboration Agreement
Issuance of common stock under ESPP
From June 30, 2019 to September 30, 2019
Exercises of vested stock options
From March 31, 2019 to June 30, 2019
Exercises of vested stock options
Issuance of common stock under ESPP
from December 31, 2018 to March 31, 2019
Exercises of vested stock options
Issuance of common stock in connection with the Neurocrine Collaboration Agreement
from December 31, 2017 to December 31, 2018
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock under ESPP
from December 31, 2016 to December 31, 2017
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock under ESPP
Issuance of common stock from public offering (net of underwriters discounts and issuance costs of $4,100)
from December 31, 2015 to December 31, 2016
Vesting of restricted stock
Exercises of vested stock options
from December 31, 2014 to December 31, 2015
Issuance of Series A preferred stock, net of issuance costs of $1
Issuance of Series B preferred stock, net of discount of $5,000 and issuance costs of $220
Vesting of restricted stock
Exercises of vested stock options
Issuance of common stock from initial public offering (net of underwriters, discounts, and issuance costs)
Conversion of redeemable convertible preferred stock to common stock
A 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015
The conversion of all outstanding convertible preferred stock into 17,647,054 shares of common stock immediately prior to the completion of this offering;
A 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015.
a 1-for-4.25 reverse stock split of our common stock and a proportional adjustment to the existing conversion ratio of each series of our convertible preferred stock, which became effective on October 29, 2015